BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3293763)

  • 1. Treatment of malignant pleural effusions with intracavitary Corynebacterium parvum.
    Casali A; Gionfra T; Rinaldi M; Tonachella R; Tropea F; Venturo I; De Martino C; Curcio CG
    Cancer; 1988 Aug; 62(4):806-11. PubMed ID: 3293763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of neoplastic pleural effusion by intrapleural administration of Corynebacterium parvum vaccine].
    Krasucka-Kluźniak A; Krakówka P
    Pneumonol Pol; 1985 May; 53(5):240-7. PubMed ID: 4047949
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
    Leahy BC; Honeybourne D; Brear SG; Carroll KB; Thatcher N; Stretton TB
    Eur J Respir Dis; 1985 Jan; 66(1):50-4. PubMed ID: 3979476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
    Marel M; Melínová L; Bednár M
    Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum. Clinical response is not associated with evidence of enhancement of local cellular-mediated immunity.
    Rossi GA; Felletti R; Balbi B; Sacco O; Cosulich E; Risso A; Melioli G; Ravazzoni C
    Am Rev Respir Dis; 1987 Apr; 135(4):885-90. PubMed ID: 2436513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions.
    Millar JW; Hunter AM; Horne NW
    Thorax; 1980 Nov; 35(11):856-8. PubMed ID: 7221983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anatomical study of the fibrosing action of Corynebacterium parvum in malignant pleural effusion].
    Foresti V; Scolari N; Villa A; Parisio E
    Minerva Med; 1989 Oct; 80(10):1069-72. PubMed ID: 2812462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.
    Webb HE; Oaten SW; Pike CP
    Br Med J; 1978 Feb; 1(6109):338-40. PubMed ID: 623981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapleural Corynebacterium parvum for malignant pleural effusions.
    Felletti R; Ravazzoni C
    Thorax; 1983 Jan; 38(1):22-4. PubMed ID: 6845257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of intracavitary bleomycin and Corynebacterium parvum in the control of malignant pleural effusions.
    Ostrowski MJ; Priestman TJ; Houston RF; Martin WM
    Radiother Oncol; 1989 Jan; 14(1):19-26. PubMed ID: 2467327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavitary Corynebacterium parvum for treatment of malignant effusions.
    Currie JL; Gall S; Weed JC; Creasman WT
    Gynecol Oncol; 1983 Aug; 16(1):6-14. PubMed ID: 6884832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions.
    Foresti V
    Respiration; 1995; 62(1):21-6. PubMed ID: 7716350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute polyarthritis following the use of Corynebacterium parvum vaccine (Coparvax) for malignant pleural effusion.
    Lever AM; Forsythe J; Oxford P
    Postgrad Med J; 1983 Dec; 59(698):799-800. PubMed ID: 6657546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax).
    Laroche CM; Britton M
    Thorax; 1987 Oct; 42(10):823-4. PubMed ID: 3424259
    [No Abstract]   [Full Text] [Related]  

  • 15. Further experience of Corynebacterium parvum in malignant pleural effusion.
    McLeod DT; Calverley PM; Millar JW; Horne NW
    Thorax; 1985 Jul; 40(7):515-8. PubMed ID: 4035618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
    Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
    Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corynebacterium parvum in malignant pleural effusion. A randomized prospective study.
    Hillerdal G; Kiviloog J; Nöu E; Steinholtz L
    Eur J Respir Dis; 1986 Sep; 69(3):204-6. PubMed ID: 2430825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corynebacterium parvum versus tetracycline as pleural sclerosing agents in rabbits.
    Vargas FS; Wang NS; Teixeira LR; Carmo AO; Silva LM; Light RW
    Eur Respir J; 1995 Dec; 8(12):2174-7. PubMed ID: 8666113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapleural natural beta interferon in the treatment of malignant pleural effusions.
    Rosso R; Rimoldi R; Salvati F; De Palma M; Cinquegrana A; Nicolò G; Ardizzoni A; Fusco U; Capaccio A; Centofanti R
    Oncology; 1988; 45(3):253-6. PubMed ID: 2453008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy of mitomycin-C and corynebacterium parvum in the management of malignant pleural effusion.
    Yew WW; Chan SL; Kwan SY
    Chin Med J (Engl); 1988 Oct; 101(10):737-9. PubMed ID: 3150706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.